주요 내용으로 건너 뛰기
/ 자료 / 온디맨드 웨비나 / PBPK modeling approaches to assess risks associated with bioequivalence in drug development

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed:

  • Opportunities and challenges in conducting virtual bioequivalence
  • IVIVE-PBPK in biopharmaceutics
  • An quantitative risk assessment approach for virtual bioequivalence
  • Role of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence
Powered by Translations.com GlobalLink Web Software